Pharmacological Study of A3 Adenosine Receptor agonist (AB Meca) in
Xenograft Lung Cancer Model in Mice through In Silico and In Vivo Approach:
Targeting TNF-α

Nilay       Solanki; Leena       Patel; Shaini       Shah; Ashish       Patel; Swayamprakash       Patel; Mehul       Patel; Umang       Shah

doi:10.2174/1570163818666210810142022

Abstract

Background: Lung cancer is the leading cause of mortality in India. Adenosine Receptor (AR) has emerged as a novel cancer-specific target. A3AR levels are upregulated in various tumor cells, which may mean that the specific AR may act as a biological marker and target specific ligands leading to cell growth inhibition.

Aim: Our aim was to study the efficacy of the adenosine receptor agonist, AB MECA, by in silico (molecular docking) and in vitro (human cancer cells in xenografted mice) studies.

Methods: Molecular docking on the AB-meca and TNF-α was performed using AutoDock. A549 Human lung cancer 2 ×10⁶ cells per microliter per mouse injected via intrabronchial route. Rat TNF-α level was assessed by ELISA method.

Results: AB Meca's predicted binding energy (beng) with TNF-α was 97.13 kcal/mol, and the compatible docking result of a small molecular inhibitor with TNF-α native ligand beng was 85.76 kcal/mol. In vivo, a single dose of lung cancer cell A549 is being researched to potentiate tumor development. Doxorubicin and A3AR agonist therapies have lowered TNF-alpha levels that were associated with in silico function. The A3AR Agonist showed myeloprotective effects in the groups treated along with doxorubicin.

Conclusion: AB MECA’s higher binding energy (beng) with TNF-α mediated reduction of tumor growth in our lung cancer in vivo model suggested that it may be an effective therapy for lung cancer.

Keywords: Molecular docking, lung cancer, A3 adenosine receptor agonist, TNF- α, doxorubicin, adenosine receptor.

Graphical Abstract

[1] 
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID:  30207593] 
[2] 
Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med  2008; 359(13): 1367-80.
[3] 
Fukuyama T, Ichiki Y, Yamada S, et al. Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci  2007; 98(7): 1048-54.
[http://dx.doi.org/10.1111/j.1349-7006.2007.00507.x] [PMID:  17511773] 
[4] 
Song XY, Zhou SJ, Xiao N, et al. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer. Asian Pac J Cancer Prev  2013; 14(8): 4765-8.
[http://dx.doi.org/10.7314/APJCP.2013.14.8.4765] [PMID:  24083740] 
[5] 
Derin D, Soydinç HO, Guney N, et al. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer. Lung Cancer  2008; 59(2): 240-5.
[http://dx.doi.org/10.1016/j.lungcan.2007.08.005] [PMID:  17875341] 
[6] 
Cacciari B, Pastorin G, Bolcato C, Spalluto G, Bacilieri M, Moro S. A2B adenosine receptor antagonists: Recent developments. Mini Rev Med Chem  2005; 5(12): 1053-60.
[http://dx.doi.org/10.2174/138955705774933374] [PMID:  16375751] 
[7] 
Haskó G, Pacher P, Deitch EA, Vizi ES. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther  2007; 113(2): 264-75.
[http://dx.doi.org/10.1016/j.pharmthera.2006.08.003] [PMID:  17056121] 
[8] 
Tautenhahn M, Leichsenring A, Servettini I, et al. Purinergic modulation of the excitatory synaptic input onto rat striatal neurons. Neuropharmacology  2012; 62(4): 1756-66.
[http://dx.doi.org/10.1016/j.neuropharm.2011.12.001] [PMID:  22182780] 
[9] 
Kellar A, Egan C, Morris D. Preclinical murine models for lung cancer: Clinical trial applications. BioMed Res Int  2015; 2015621324
[http://dx.doi.org/10.1155/2015/621324] [PMID:  26064932] 
[10] 
Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: The good, the bad and the ugly effect. Curr Med Chem  2009; 16(25): 3267-85.
[http://dx.doi.org/10.2174/092986709788803312] [PMID:  19548866] 
[11] 
Zheng Z, Pavlidis P, Chua S, D’Agati VD, Gharavi AG. An ancestral haplotype defines susceptibility to doxorubicin nephropathy in the laboratory mouse. J Am Soc Nephrol  2006; 17(7): 1796-800.
[http://dx.doi.org/10.1681/ASN.2005121373] [PMID:  16775033] 
[12] 
Rook M, Lely AT, Kramer AB, van Goor H, Navis G. Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage. Nephrol Dial Transplant  2005; 20(1): 59-64.
[http://dx.doi.org/10.1093/ndt/gfh579] [PMID:  15572383] 
[13] 
Wang Y, Wang YP, Tay YC, Harris DC. Role of CD8(+) cells in the progression of murine adriamycin nephropathy. Kidney Int  2001; 59(3): 941-9.
[http://dx.doi.org/10.1046/j.1523-1755.2001.059003941.x] [PMID:  11231349] 
[14] 
Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res  2000; 28(1): 235-42.
[http://dx.doi.org/10.1093/nar/28.1.235] [PMID:  10592235] 
[15] 
He MM, Smith AS, Oslob JD, et al. Small-molecule inhibition of TNF-&#945. Science  2005; 310(5750): 1022-5.
[http://dx.doi.org/10.1126/science.1116304] [PMID:  16284179] 
[16] 
Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem  2009; 30(16): 2785-91.
[http://dx.doi.org/10.1002/jcc.21256] [PMID:  19399780] 
[17] 
Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH. PubChem: A public information system for analyzing bioactivities of small molecules. Nucleic Acids Res  2009; 37: 632-3.
[http://dx.doi.org/10.1093/nar/gkp456] 
[18] 
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem  2010; 31(2): 455-61.
[PMID:  19499576] 
[19] 
Mikus EG, Szeredi J, Boer K, et al. Evaluation of SSR161421, a novel orally active adenosine A3 receptor antagonist on pharmacology models. Eur J Pharmacol  2013; 699(1-3): 172-9.
[http://dx.doi.org/10.1016/j.ejphar.2012.11.049] [PMID:  23219796] 
[20] 
Chougule MB, Patel AR, Jackson T, Singh M. Antitumor activity of noscapine in combination with doxorubicin in triple negative breast cancer. PLoS One  2011; 6(3)e17733
[http://dx.doi.org/10.1371/journal.pone.0017733] [PMID:  21423660] 
[21] 
Dikmen ZG, Gellert GC, Jackson S, et al. in vivo inhibition of lung cancer by GRN163L: A novel human telomerase inhibitor. Cancer Res  2005; 65(17): 7866-73.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-1215] [PMID:  16140956] 
[22] 
Li B, Torossian A, Li W, et al. A novel bioluminescence orthotopic mouse model for advanced lung cancer. Radiat Res  2011; 176(4): 486-93.
[http://dx.doi.org/10.1667/RR2565.1] [PMID:  21663394] 
[23] 
Paulus MJ, Gleason SS, Kennel SJ, Hunsicker PR, Johnson DK. High resolution X-ray computed tomography: An emerging tool for small animal cancer research. Neoplasia  2000; 2(1-2): 62-70.
[http://dx.doi.org/10.1038/sj.neo.7900069] [PMID:  10933069] 
[24] 
Bar-Yehuda S, Stemmer SM, Madi L, et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol  2008; 33(2): 287-95.
[PMID:  18636149] 
[25] 
Enewold L, Mechanic LE, Bowman ED, et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev  2009; 18(1): 215-22.
[http://dx.doi.org/10.1158/1055-9965.EPI-08-0705] [PMID:  19124500] 
[26] 
Dong X, Guan J, English JC, et al. Patient-derived first generation xenografts of non-small cell lung cancers: Promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res  2010; 16(5): 1442-51.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-2878] [PMID:  20179238] 
[27] 
Giacosa A, Frascio F, Sukkar SG, Roncella S. Food intake and body composition in cancer cachexia. Nutrition  1996; 12(1)(Suppl.): S20-3.
[http://dx.doi.org/10.1016/0899-9007(95)00065-8] [PMID:  8850214] 
[28] 
Solanki N, Patel L, Patel A. in vitro evaluation of the anti-cancer potential of a3 adenosine receptor agonist on a549 human lung cancer cell line. Int J Pharm Pharm Sci  2019; 11(6): 106-8.
[http://dx.doi.org/10.22159/ijpps.2019v11i6.30863] 
[29] 
Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today  2012; 17(7-8): 359-66.
[http://dx.doi.org/10.1016/j.drudis.2011.10.007] [PMID:  22033198] 

Rights & Permissions Print Cite

Article Metrics

19

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1570163818666210810142022	Print ISSN 1570-1638
Publisher Name Bentham Science Publisher	Online ISSN 1875-6220

Current Drug Discovery Technologies

Pharmacological Study of A3 Adenosine Receptor agonist (AB Meca) in Xenograft Lung Cancer Model in Mice through In Silico and In Vivo Approach: Targeting TNF-α

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract